We tested the hypothesis that cumulative excess incidence (CEI), a measure of excess prostate cancer diagnoses (each diagnosis generally accomplished via PSA screening with associated biopsy if indicated), is related to reduced prostate cancer mortality through analysis of data from SEER in the US, using an approach distinct from that employed in the randomized controlled trials reviewed above. Here, KLK3 is linked to prostate carcinoma.